Supernus Pharmaceuticals Inc (SUPN) Given Consensus Rating of “Buy” by Brokerages

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has earned an average recommendation of “Buy” from the twelve brokerages that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $50.33.

A number of equities research analysts have issued reports on SUPN shares. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 10th. FBR & Co initiated coverage on shares of Supernus Pharmaceuticals in a research note on Thursday, October 19th. They issued a “buy” rating and a $53.00 target price for the company. Janney Montgomery Scott raised shares of Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Monday, December 4th. Stifel Nicolaus raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Tuesday, November 7th. Finally, Cowen set a $50.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 23rd.

In other news, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $43.56, for a total transaction of $2,178,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Victor Vaughn sold 55,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $40.11, for a total transaction of $2,206,050.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 145,750 shares of company stock valued at $6,173,173. Insiders own 6.70% of the company’s stock.

Several large investors have recently modified their holdings of SUPN. BlackRock Inc. lifted its holdings in Supernus Pharmaceuticals by 0.5% in the second quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock valued at $289,962,000 after acquiring an additional 31,331 shares during the period. Vanguard Group Inc. grew its stake in shares of Supernus Pharmaceuticals by 39.1% during the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after buying an additional 984,200 shares during the period. State Street Corp grew its stake in shares of Supernus Pharmaceuticals by 3.1% during the 2nd quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock valued at $60,230,000 after buying an additional 42,165 shares during the period. Acadian Asset Management LLC boosted its position in Supernus Pharmaceuticals by 2.0% during the 4th quarter. Acadian Asset Management LLC now owns 1,280,179 shares of the specialty pharmaceutical company’s stock worth $51,013,000 after purchasing an additional 24,491 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Supernus Pharmaceuticals by 10.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock worth $54,654,000 after purchasing an additional 122,042 shares during the period. Institutional investors own 98.22% of the company’s stock.

Supernus Pharmaceuticals (NASDAQ SUPN) traded down $2.95 on Friday, reaching $43.55. 904,600 shares of the company traded hands, compared to its average volume of 706,475. The firm has a market capitalization of $2,390.00, a price-to-earnings ratio of 39.59 and a beta of 1.17. Supernus Pharmaceuticals has a 52-week low of $23.10 and a 52-week high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The firm had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. The company’s revenue for the quarter was up 41.5% on a year-over-year basis. analysts anticipate that Supernus Pharmaceuticals will post 1.07 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/19/supernus-pharmaceuticals-inc-supn-given-consensus-rating-of-buy-by-brokerages.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply